SynerFuse completed enrollment in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF) procedure that integrates spinal fusion with direct nerve stimulation, and is designed to treat neuropathic chronic lower back pain.
The SynerFuse e-TLIF procedure is designed to avoid the treatment failure, multiple spinal fusions and opioid therapy that typically precedes a neuromodulation implant.
SynerFuse has 11 issued patents and 70 published applications worldwide for its novel e-TLIF procedure.
“The progress we have made demonstrates our commitment to design the SynerFuse e-TLIF procedure in a manner aimed at avoiding treatment failure, multiple spinal fusions, and risky opioid therapy,” said Justin Zenanko, President and CEO. “With this milestone, we advance our mission to improve patient quality of life and address the opioid crisis head on.”
SynerFuse completed enrollment in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF) procedure that integrates spinal fusion with direct nerve stimulation, and is designed to treat neuropathic chronic lower back pain.
The SynerFuse e-TLIF procedure is designed to...
SynerFuse completed enrollment in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF) procedure that integrates spinal fusion with direct nerve stimulation, and is designed to treat neuropathic chronic lower back pain.
The SynerFuse e-TLIF procedure is designed to avoid the treatment failure, multiple spinal fusions and opioid therapy that typically precedes a neuromodulation implant.
SynerFuse has 11 issued patents and 70 published applications worldwide for its novel e-TLIF procedure.
“The progress we have made demonstrates our commitment to design the SynerFuse e-TLIF procedure in a manner aimed at avoiding treatment failure, multiple spinal fusions, and risky opioid therapy,” said Justin Zenanko, President and CEO. “With this milestone, we advance our mission to improve patient quality of life and address the opioid crisis head on.”
Copy to clipboard 
